GLP-1 receptor agonists now represent a cornerstone of therapy for both T2DM and obesity, with consistent benefits on glycemic control, body weight, and cardiovascular and renal outcomes [129, 255]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.